Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor‑positive advanced breast cancer that progressed on prior endocrine therapy: A meta‑analysis
Open Access
- 18 July 2022
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 24 (3) , 1-8
Abstract
Currently, endocrine therapy is the standard treatment for hormone receptor‑positive advanced breast cancer (ABC). Despite the high sensitivity of anti‑estrogen therapy, many breast cancer patients still experience disease progression, relapse, and reduced overall survival (OS) because of endocrine resistance. Several underlying mechanisms of this phenomenon include a change in hormone receptor expression, mutations in ESR1 and modification of important signaling pathways, but thus far none of these can be defined as the complete explanation. Additionally, it has been shown that in some breast cancers, expression of the estrogen receptor (ER) can be repressed by epigenetic modifications such as DNA methylation and histone deacetylation, and this could be a mechanism for endocrine resistance. Interestingly, although the efficacy of the combination of histone deacetylase (HADC) inhibitors and exemestane in hormone receptor‑positive ABC that progressed on prior endocrine therapy has been investigated in several studies, whether pharmacologic blocking of HDAC activity acts as a therapeutic strategy remains highly controversial. Herein, we conducted a meta‑analysis to evaluate the efficacy and safety of an HDAC inhibitor plus exemestane vs. exemestane alone in this setting. Our meta‑analysis demonstrated that the combination group exhibited significantly prolonged progression‑free survival (PFS) [hazard ratio (HR)=0.776, 95% confidence interval (CI)=0.675‑0.892, P=0.000] and an improved objective response rate (ORR) (RR=1.612, 95% CI=1.085‑2.396, P=0.018) compared to those treated with exemestane alone. Additionally, in terms of OS, the combination group failed to achieve a significant clinical OS benefit (HR=0.811, 95% CI=0.596‑1.104, P=0.183). Although grade 3/4 toxicities were more common in the combination group, those toxicities were mostly asymptomatic and manageable. In conclusion, the addition of an HDAC inhibitor to exemestane significantly improves PFS over exemestane alone in hormone receptor‑positive ABC patients who progressed on previous endocrine therapy. Identification of novel biomarkers to select patients who will benefit from this combination strategy is a high priority.Keywords
This publication has 34 references indexed in Scilit:
- Effects of ovarian ablation or suppression in premenopausal breast cancer: A meta-analysis of randomized controlled trialsEuropean Journal of Surgical Oncology, 2017
- The impact of pyrvinium pamoate on colon cancer cell viabilityInternational Journal of Colorectal Disease, 2014
- Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase InhibitorJournal of Clinical Oncology, 2013
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancerBritish Journal of Cancer, 2011
- Functional Activation of the Estrogen Receptor-α and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to LetrozoleCancer Research, 2011
- Her2 cross talk and therapeutic resistance in breast cancerFrontiers in Bioscience-Landmark, 2008
- Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE StudyJournal of Clinical Oncology, 2007
- Heterogeneity testing in meta‐analysis of genome searchesGenetic Epidemiology, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003